Rapid Electrochemical Quantification for In Vitro Release Trait of Ophthalmic Drug Loaded within Mucoadhesive Metal Organic Framework (MOF)

Abstract

Limited residence time of drugs in the ocular surface, poor bioavailability and side effects are the major challenges in ophthalmic treatment. From the last decade, the pharmaceutical industry is in search of a reliable ophthalmic drug delivery system. In the present study, we demonstrate amine‐functionalized mucoadhesive MIL88B(FeMOF) as a drug delivery cargo to encapsulate ophthalmic drug Timolol (TM) at a rate of 195 μg/mg. Invitro release of TM (only upto 63 %) from loaded FeMOF (TM@FeMOF) within 10 h without burst effect was a noticeable feature that anticipates enhanced preocular retention by the sustained release of TM through extensive H‐bonding of the amine group of MOFs with mucin. A novel and facile approach using Differential Pulse Voltammetry (DPV) were harnessed for rapid quantification of TM during in‐vitro release studies, further validated by HPLC measurement(<10 % deviation). The encouraging results from in‐vitro studies forecast the success story of TM@FeMOF as a biocompatible, biodegradable, and sustainable ophthalmic drug delivery system.

Bacteria-Targeting Nanoparticles with ROS-Responsive Antibiotic Release to Eradicate Biofilms and Drug-Resistant Bacteria in Endophthalmitis

“…Additionally, previous studies suggest that π-π interactions between the aromatic rings of the drug and the MOF material facilitate the physical adsorption of the drug. 37 , 38

Figure 1 Structural and physio-chemical characterization of MXF@UiO-UBI-PEGTK. ( A ) TEM images of UiO-66, MXF@UiO, and MXF@UiO-UBI-PEGTK.

…”

“…Additionally, previous studies suggest that π-π interactions between the aromatic rings of the drug and the MOF material facilitate the physical adsorption of the drug. 37,38…”

“…To address the challenge of biofilm formation, UiO-66 was used to absorb MXF, followed by the immobilization of UBI [29][30][31][32][33][34][35][36][37][38][39][40][41] . Subsequently, we introduced PEG-TK to modify the surface of the NPs to construct an ROS-sensitive drug delivery system-the final complex NPs (MXF@UiO-UBI-PEGTK) (Scheme 1).…”